# Lymphoma (tissue type)

Source: https://onco.cc/terms/lymphoma-type/  
OnCo record `lymphoma-type` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Cancer of lymphocytes, the white blood cells of the immune system, usually growing as masses in lymph nodes, spleen or other organs. It is divided into Hodgkin lymphoma and the non-Hodgkin lymphomas, most of which arise from B cells and keep surface markers such as CD20 that antibodies, ADCs and CAR-T can target.

## Summary

Most lymphomas arise from B cells and keep surface markers such as CD19, CD20 and CD30, which has made them the proving ground for antibody therapy (rituximab, 1997), ADCs (brentuximab vedotin), CAR-T (axicabtagene, 2017) and bispecific T-cell engagers (glofitamab); diffuse large B-cell lymphoma is the commonest type and is often curable with chemo-immunotherapy. Hodgkin lymphoma, defined by its Reed-Sternberg cells, is highly curable and exceptionally responsive to PD-1 blockade. Lymphomas and leukaemias overlap: the same malignant lymphocyte can present as a mass (lymphoma) or circulate in the blood (leukaemia).

## Fields

- Kind: Term
- Last checked: 2026-09-09
- Also known as: lymphomas; lymphoid malignancy; lymphoid malignancies; Hodgkin; non-Hodgkin; B-cell lymphoma; B-cell lymphomas; T-cell lymphoma; T-cell lymphomas

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Lymphoma
- Wikipedia: https://en.wikipedia.org/wiki/Lymphoma

## Connected records

- terms: [Antibody](https://onco.cc/terms/antibody/), [B cell](https://onco.cc/terms/b-cell/), [B-cell, T-cell and NK-cell lymphoma](https://onco.cc/terms/lymphoma-b-versus-t-cell/), [Carcinoma](https://onco.cc/terms/carcinoma/), [HTLV-1 (human T-lymphotropic virus type 1)](https://onco.cc/terms/lymphoma-htlv-1/), [Indolent and aggressive lymphoma](https://onco.cc/terms/lymphoma-indolent-versus-aggressive/), [Leukaemia (tissue type)](https://onco.cc/terms/leukaemia-type/), [Lymph node](https://onco.cc/terms/lymph-node/), [Nodal and extranodal lymphoma](https://onco.cc/terms/lymphoma-nodal-versus-extranodal/), [Sarcoma (tissue type)](https://onco.cc/terms/sarcoma-type/), [T cell](https://onco.cc/terms/t-cell/), [The two lymphoma classifications of 2022 (WHO-HAEM5 and ICC)](https://onco.cc/terms/lymphoma-classification-2022/)
- cancers: [Burkitt lymphoma](https://onco.cc/cancers/burkitt-lymphoma/), [Chronic lymphocytic leukaemia](https://onco.cc/cancers/cll/), [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/), [Hodgkin lymphoma](https://onco.cc/cancers/hodgkin-lymphoma/), [Mycosis fungoides](https://onco.cc/cancers/mycosis-fungoides/), [Nodular lymphocyte-predominant Hodgkin lymphoma (nodular lymphocyte-predominant B-cell lymphoma)](https://onco.cc/cancers/nodular-lymphocyte-predominant-hodgkin-lymphoma/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/), [Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma)](https://onco.cc/cancers/peripheral-t-cell-lymphoma/)
- technologies: [CAR-T cell therapy](https://onco.cc/technologies/car-t/), [T-cell engagers (bispecific)](https://onco.cc/technologies/t-cell-engager/)
- targets: [CD19](https://onco.cc/targets/cd19/), [CD20](https://onco.cc/targets/cd20/)
- drugs: [Axicabtagene ciloleucel](https://onco.cc/drugs/axicabtagene-ciloleucel/), [Brentuximab vedotin](https://onco.cc/drugs/brentuximab-vedotin/), [Glofitamab](https://onco.cc/drugs/glofitamab/)

---
JSON: https://onco.cc/api/v1/entities/lymphoma-type.json